Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Unit price / market price
-
$0.8156
-
Total 13F principal
-
$273,236,000
-
Principal change
-
+$23,853,000
-
Total reported value
-
$226,785,000
-
Number of holders
-
18
-
Value change
-
+$15,533,536
-
Number of buys
-
6
-
Number of sells
-
9
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2022
As of 30 Jun 2022 REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 had 18 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $273,236,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Kohlberg Kravis Roberts & Co. L.P., FRANKLIN RESOURCES INC, COWEN AND COMPANY, LLC, LAZARD ASSET MANAGEMENT LLC, AVIVA PLC, UBS OCONNOR LLC, ZAZOVE ASSOCIATES LLC, Antara Capital LP, CAPSTONE INVESTMENT ADVISORS, LLC, and AMUNDI.
This table shows 18 bond principal holders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.